News

Venrock led the Series B financing and was joined by five additional new investors: Andera (formerly Edmond de Rothschild), Cormorant Asset Management, HBM Healthcare Investments, Fresenius Medical Care

Risankizumab is a humanized monoclonal antibody, designed to selectively inhibit IL-23 by binding to its p19 subunit. IL-23 is an important cytokine involved in inflammatory processes, and is

The new indication is for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. It is also indicated to reduce

This randomised, open-label, multi-centre trial assessed the efficacy and safety of the combination of Imfinzi (durvalumab) plus tremelimumab, as well as Imfinzi and tremelimumab monotherapies, versus standard-of-care chemotherapy

As per the revised proposal, Takeda offers to pay nearly £49 per each share of Shire in the form of £21.75 in cash and £27.26 in new Takeda

The Phase 2b  Pronto study did not meet its primary or secondary endpoints. A phase 3 Vital Amyloidosis study is also being discontinued based on futility analysis. AL amyloidosis is a

Zymeworks president & CEO Ali Tehrani said: “The team at Celgene has made excellent progress developing bispecific and multifunctional therapeutic candidates built on our industry-leading Azymetric platform and

Pfizer said that the additional requested information asked in the Complete Response Letter (CRL) sent by the US regulator is not related to safety or clinical data submitted

The partnership will use Biogen’s expertise in neuroscience research and drug development and Ionis’ capabilities in RNA targeted therapies to develop a range of investigational therapies. As per